Xeris Pharmaceuticals Inc Stock News

Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with

Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing

Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Diseas

Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotum

Xeris Biopharma (NASDAQ: XERS ) stock is heading higher on Wednesday after the company announced an exclusive worldwide license agreement with Amgen (NASDAQ: AMGN ). That agreement allows Amgen to dev

Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platform

2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing.

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it remains on track to be cashflow positive in the fourth quarter of 2024 as it updated its revenue and cash position guidance for its 2023 financ

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial

Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to

Penny stocks, usually under $5 a share, draw traders looking for big gains. But these stocks can be risky.

Xeris Biopharma Holdings (NASDAQ:XERS) revealed its latest quarterly results that highlighted strong revenue growth driven by its commercial products. “We continue to demonstrate record revenue grow